Ellen Feigal Sells Shares of Xencor, Inc.
Ellen Feigal sold 6,843 shares of Xencor on June 18, 2026, under a planned transaction.
Key Points
- Ellen Feigal sold 6,843 shares of Xencor, Inc. on June 18, 2026, for $89,369.58 under a planned sale.
- Shares of Xencor traded near $14.01 on Tuesday with a market cap of about $1.04 billion and no meaningful P/E ratio.
- JP Morgan maintained a hold rating on Xencor with a $14 target price, while Barclays kept a buy rating with a $27 target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Ellen Feigal, an insider at Xencor, Inc., sold 6,843 shares of the company on June 18, 2026. The shares were sold at an average price of $13.06, totaling $89,369.58. This sale was part of a planned transaction under Rule 10b5-1.
Insider Buying and Selling at Xencor, Inc.
In addition to Ellen Feigal, several other insiders at Xencor have recently sold shares. On June 15, 2026, Richard Ranieri, Kevin Charles Gorman, Kurt Gustafson, and Alan Bruce Montgomery each sold shares at an average price of $12.31. Bart Jan Cornelissen, the Senior Vice President and CFO, sold 3,499 shares on April 10, 2026, at $12.29, though this was not a planned sale.
Xencor, Inc. Stock Down 46.2%
Shares of NasdaqGM:XNCR traded near $14.01 on Tuesday. Xencor has a market capitalization of approximately $1.04 billion. The company does not have a meaningful P/E ratio as it is not currently profitable. Its beta is 0.928, indicating lower volatility compared to the market. Xencor's stock has seen a 52-week low of $6.92 and a high of $18.69. The 50-day moving average is $12.16, and the 200-day moving average is $12.87. The company's current ratio stands at 6.57, with a quick ratio of 6.22 and a debt-to-equity ratio of 33.97.
$XNCR stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 11, 2026, JP Morgan maintained its hold rating on Xencor with a price target of $14. Barclays, on February 26, 2026, maintained a buy rating with a target price of $27. The consensus among analysts is a strong buy, with a mean target price of $28.50 based on 12 analyst opinions.
About Xencor, Inc.
Xencor, Inc. is a biotechnology company headquartered in Pasadena, California. It focuses on developing engineered antibodies for cancer and autoimmune diseases. The company offers treatments like Ultomiris and Monjuvi for various conditions and is working on a range of other antibody therapies. Dr. Bassil I. Dahiyat is the CEO, and the company employs around 260 people.
Bottom Line
Ellen Feigal's recent sale of Xencor shares is part of planned insider trading activity. Investors keep a close watch on insider transactions as they can provide insight into a company's prospects. However, it's important to remember that such sales do not necessarily indicate negative sentiment. Xencor, with its focus on innovative treatments, continues to be a company to watch in the biotechnology sector.
Get Xencor, Inc. alerts
New 13F filings, insider trades, and analyst moves on $XNCR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.